Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced that Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 12:00 p.m. ET. The company noted a live and archived webcast will be available via the Opus Genetics investor website under Events.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, IRD declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:00 p.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, please visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

When will Opus Genetics (IRD) present at Chardan's 9th Annual Genetic Medicines Conference?

Opus Genetics will present on Tuesday, October 21, 2025 at 12:00 p.m. ET.

Who is presenting for Opus Genetics (IRD) at the October 21, 2025 conference?

Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will deliver the corporate update.

How can investors watch the Opus Genetics (IRD) presentation on October 21, 2025?

A live webcast and archived replay will be available on the Opus Genetics investor website under Events.

What topics will Opus Genetics (IRD) cover in the October 21, 2025 corporate update?

The company said the presentation is a corporate update; no additional topics or clinical details were specified in the announcement.

Is the Opus Genetics (IRD) webcast for the Chardan conference free to access?

The announcement states the webcast will be available on the company's investor website; it does not mention any fees.